FDA

To protect medical and health research, policy makers must eliminate sequestration. This remains Research!America’€™s top-line message, because it is sequestration that poses the greatest threat to all discretionary funding, including medical and health research conducted by NIH, CDC, FDA, NSF, AHRQ, DOD ’€¦ and the list goes on. Advocates for medical and health research have made a huge impact over the years on funding and policies supportive of medical and health research, including playing a key role in reducing sequestration in 2013. We are asking you to weigh in again to help address sequestration in FY14 and FY15. On Wednesday, the co-chairs of the committee charged with establishing...
To address the recent meningitis outbreak at Princeton, public health programs from all levels got involved. Students sought medical attention at the university’€™s health center and their hometown local hospitals; the New Jersey Department of Health (NJDOH) investigated the outbreak and requested CDC involvement; the FDA examined the case and allowed a new vaccine, unlicensed in the US but approved in Europe and Australia. With final CDC approval, the university will offer the vaccine on campus and cover the cost for all students. Diverse institutions within our public health infrastructure came together to address the outbreak, and the public health professionals within them did what was...
Urge your Members to protect medical research in upcoming Budget Conference Committee discussions Sequestration’€™s arbitrary, across-the-board budget cuts to defense and non-defense spending have ravaged (and will continue to ravage) our research enterprise. The Budget Conference Committee, which was negotiated as part of reopening the government and preventing the U.S. from defaulting on debts, has an opportunity to replace sequestration as they develop their ’€œlong-term budget solution’€ by December 13. Sequestration is rendering it virtually impossible to maintain, much less increase the budgets of NIH, NSF, FDA, and CDC; if it is not stopped, their budgets will almost certainly...
Bart Peterson, JD, Senior Vice President for Corporate Affairs and Communications at Eli Lilly , and the keynote speaker of the Research!America’s National Research Health Forum talked with Medscape about the future of research and drug development, and whether cooperation between industry and the US Food and Drug Administration (FDA) can ever truly exist. To see the interview, click here .
By Robert J. Hariri, MD, PhD, Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics . Medical innovation is the source of dramatic improvements in the quality and length of life and also creates enormous value for society and the economy at large. For example, in 1900, the average U.S. life expectancy was 49 years. Today, it is 79. It is estimated by 2040, U.S. life expectancy will reach 85 years. This is primarily the result of innovation in medicine and improvements to public health. New medical treatments accounted for 45 percent of the increase in U.S. life expectancy between 1960 and 1997 and for nearly three-quarters of the increase in U.S life expectancy in...
By Robert J. Hariri, MD, PhD, Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics . Medical innovation is the source of dramatic improvements in the quality and length of life and also creates enormous value for society and the economy at large. For example, in 1900, the average U.S. life expectancy was 49 years. Today, it is 79. It is estimated by 2040, U.S. life expectancy will reach 85 years. This is primarily the result of innovation in medicine and improvements to public health. New medical treatments accounted for 45 percent of the increase in U.S. life expectancy between 1960 and 1997 and for nearly three-quarters of the increase in U.S life expectancy in...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...

Pages

Sidebar Quote

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America